Non-invasive detection of fetal genetic traits

Abstract

Blood plasma of pregnant women contains fetal and (generally >90%) maternal circulatory extracellular DNA. Most of said fetal DNA contains 500 base pairs, said maternal DNA having a greater size. Separation of circulatory extracellular DNA of <500 base pairs results in separation of fetal from maternal DNA. A fraction of a blood plasma or serum sample of a pregnant woman containing, due to size separation (e.g. by chromatography, density gradient centrifugation or nanotechnological methods), extracellular DNA substantially comprising 500 base pairs is useful for non-invasive detection of fetal genetic traits (including the fetal RhD gene in pregnancies at risk for HDN; fetal Y chromosome-specific sequences in pregnancies at risk for X chromosome-linked disorders; chromosomal aberrations; hereditary Mendelian genetic disorders and corresponding genetic markers; and traits decisive for paternity determination) by e.g. PCR, ligand chain reaction or probe hybridization techniques, or nucleic acid arrays.

What is claimed is: 
     
         1 . A composition, produced by a process comprising:
 (a) extracting DNA comprising maternal and fetal DNA fragments from a substantially cell-free sample of blood plasma or blood serum of a pregnant human female;   (b) producing a composition of the DNA extracted in (a) by:
 (i) size discrimination of extracellular circulatory fetal and maternal DNA fragments, and 
 (ii) selectively removing the DNA fragments greater than approximately 300 base pairs, 
   
       wherein the DNA composition after (b) comprises extracellular circulatory fetal and maternal DNA fragments of approximately 300 base pairs and less and a plurality of genetic loci of the extracellular circulatory fetal and maternal DNA fragments. 
     
     
         2 . The composition of  claim 1 , wherein the DNA fragments are in solution. 
     
     
         3 . The composition of  claim 1 , wherein the composition facilitates non-invasive detection of fetal genetic traits. 
     
     
         4 . The composition of  claim 3 , wherein the fetal genetic trait is involved in a chromosomal aberration. 
     
     
         5 . The composition of  claim 4 , wherein the chromosomal aberration is a chromosome aneuploidy. 
     
     
         6 . The composition of  claim 5 , wherein the chromosome aneuploidy is associated with Down's syndrome. 
     
     
         7 . The composition of  claim 1 , wherein the composition is in a container. 
     
     
         8 . The composition of  claim 1 , in association with a solid phase, wherein the solid phase is not a gel. 
     
     
         9 . The composition of  claim 1 , wherein (b) comprises chromatography. 
     
     
         10 . The composition of  claim 9 , wherein the chromatography comprises high performance liquid chromatography. 
     
     
         11 . The composition of  claim 1 , wherein (b) comprises electrophoresis. 
     
     
         12 . The composition of  claim 11 , wherein the electrophoresis comprises capillary electrophoresis. 
     
     
         13 . The composition of  claim 1 , wherein (b) comprises centrifugation. 
     
     
         14 . The composition of  claim 13 , wherein the centrifugation includes density gradient centrifugation. 
     
     
         15 . The composition of  claim 1 , wherein (b) comprises a nanotechnological means. 
     
     
         16 . The composition of  claim 3 , wherein non-invasive detection of fetal genetic traits comprises analyzing the composition by using nucleic acid arrays. 
     
     
         17 . The composition of  claim 3 , wherein non-invasive detection of fetal genetic traits comprises analyzing the composition by amplifying DNA. 
     
     
         18 . The composition of  claim 17 , wherein the amplifying comprises use of a polymerase chain reaction. 
     
     
         19 . The composition of  claim 17 , wherein the amplifying comprises use of a ligase chain reaction.